Recently, the Office of Talent Work Leading Group of the CPC Shanghai  Pudong New Area Committee awarded the honorary certificates and trophies to the overseas high-level talent who were selected as the “Pearl Elite Talent” in 2024 in Pudong New Area.

Dr. Zhengqing Ye, as the medicinal chemistry leader of Leadingtac's targeted protein degradation project, was selected as one of the “Pearl Elite Talent” of Pudong New Area in 2024 after passing the rigorous evaluation by the Talent Expert Group of the Pudong New Area Committee due to his many years of experience in R&D of small molecule new drugs, his outstanding R&D achievements and his excellent overseas working experience.

Previously, Dr. Zhengqing Ye has won the honor of “Pujiang Talent” for Leadingtac's targeted protein degradation project, and this year, Dr. Ye has won the honor of “Pearl Elite Talent” for his new R&D project and his solid professional background, which is not only a recognition of his personal scientific research ability and contribution, but also a recognition of his innovation ability and market prospect in the field of biopharmaceuticals. This honor is not only a recognition of his personal scientific research ability and contribution, but also a recognition of Leadingtac's innovation ability and market prospect in the field of biopharmaceuticals.

About "Pearl Talent Plan":

The "Pearl Plan" is a special policy to support the development of four types of strategic scientific and technological talent by focusing on the major tasks of building a leading area for the construction of socialist modernization and a high-level talent highland, relying on national laboratories, high-level research universities, national scientific research institutes, and scientific and technological leading enterprises, introducing globally a group of high-level overseas talent, who already stood at the international scientific and technological frontiers and led the independent innovation of science and technology, discovering and cultivating a group of innovative and entrepreneurial talent with leading roles or high growth potentials, focusing on the three major pioneering industries and other key industries, and keeping in view the cultivation of new racetracks.

About Leadingtac:

Leadingtac is a clinical-stage biopharmaceutical company based in Zhangjiang, Shanghai. The company is founded in 2019, dedicated to First-in-class/Best-in-class small molecule innovative drug discovery and development, focusing on autoimmune and oncology, two disease areas with many unmet clinical needs, with Targeted Protein Degradation (TPD) drug discovery and development technology at its core business.  Leadingtac currently has a laboratory and office area of about 2,000 square meters, with 20 formal employees and has completed three rounds of funding since its establishment.